Erisyon

Executive Summary

Erisyon is pioneering the world's first single-molecule protein sequencer using its proprietary Fluorosequencing technology, aiming to bring the transformative power of next-generation sequencing from genomics to proteomics. By enabling direct, high-throughput protein sequencing at the single-molecule level, the platform promises to revolutionize disease detection, therapeutic development, and disease progression monitoring. Current proteomic methods are limited in sensitivity and throughput, but Erisyon's approach could unlock earlier diagnoses and more precise biomarker tracking, addressing a critical gap in precision medicine. Founded in 2018 and based in Austin, Texas, the company is well-positioned to disrupt the $100B+ proteomics market. Though still in a pre-commercialization phase, Erisyon has likely made significant technical progress, with potential validation through academic partnerships or pilot studies. The company's path to market involves scaling its sequencer for research use and eventually clinical diagnostics, which may require regulatory approvals. Given the strong demand for novel proteomic tools and Erisyon's first-mover advantage, the technology could attract substantial venture funding or strategic partnerships with pharmaceutical and diagnostic companies. Near-term milestones include platform optimization, initial customer adoption, and securing capital to support expansion. Conviction is tempered by the technical challenges of commercializing a novel instrument and the competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026Publication of key proof-of-concept data or peer-reviewed study75% success
• 2026Series B or Series C financing round from top-tier investors65% success
• 2027First commercial sale or early-access partnership for the protein sequencer40% success